Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 10c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.27), $0.10 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $11.61 million versus the consensus estimate of $8.07 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Trump on Iran: we're trying to work out a deal that's fair
• Backblaze (BLZE) call put ratio 12.9 calls to 1 put with a focus on July 12.50 calls as share price up 40%
• Varonis Systems (VRNS) call put ratio 4.4 calls to 1 put with a focus on July 35, 40 and 45 calls as share price up 6.4%